Hayashi A et al., 2024-12: Lung (NSCLC) cell study: ivermectin plus paclitaxel inhibited A549 growth and prevented paclitaxel resistance by suppressing P-glycoprotein via EGFR/ERK/Akt/NF-kB.
Notably, the simultaneous ivermectin treatment during the gradual exposure completely abolished P-gp expression, leading to an increased intracellular PTX concentration and sustained PTX sensitivity.
Hayashi A et al., 2024-12: Lung (NSCLC) cell study: ivermectin plus paclitaxel inhibited A549 growth and prevented paclitaxel resistance by suppressing P-glycoprotein via EGFR/ERK/Akt/NF-kB. C7 lung cancer. Study type: cell lines only (A549 and a paclitaxel-resistant derivative); no animals, no patients. Country: Japan (Nippon Medical School, Tokyo; RIKEN). Concentration: not stated in the abstract captured. Funder/conflicts: not captured in the PubMed record. Comparator: paclitaxel alone, and drug-sensitive parental cells. Records an effect of the COMBINATION and of co-administration during resistance induction – it does not report single-agent ivermectin tumour regression or any clinical outcome. Also filed as IVC-30 (claims C5, C7). Study type: lab.
